Merck(US:MRK) Globenewswire·2025-10-08 18:59Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Merck & Co., Inc. following a class action lawsuit alleging breaches of fiduciary duties by the board of directors during the class period from February 3, 2022, to February 3, 2025 [1][6]. Group 1: Class Action Lawsuit Details - The class action lawsuit claims that Merck made false or misleading statements regarding its revenue outlook and growth of Gardasil, while downplaying competition and drug approval risks [6]. - It is alleged that Merck's optimistic reports on growth and demand in China were not reflective of the actual situation, leading to a significant decline in Gardasil's market performance [6]. - Following a disclosure on July 30, 2024, regarding a significant drop in shipments, Merck's stock price fell nearly 10% [6]. - On February 4, 2025, Merck reported a 3% decline in GARDASIL/GARDASIL 9 sales to $8.6 billion, with a more than 9% drop in stock price following this announcement [6]. Group 2: Legal Representation and Contact Information - Bragar Eagel & Squire, P.C. offers legal representation for individual and institutional investors in complex litigation [4]. - Investors who suffered losses in Merck are encouraged to contact the firm for more information regarding their rights and potential claims [3][7].